ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study.

被引：2
|
作者：
Takiuchi, Hiroya
Sasaki, Yasutsuna
Nishina, Tomohiro
Yasui, Hirofumi
Muro, Kei
Tsuji, Akihito
Koizumi, Wasaburo
Toh, Yasushi
Hara, Takuo
Miyata, Yoshinori
机构：
[1] Osaka Med Coll, Osaka, Japan
[2] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[3] Natl Hosp Org, Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Kochi Hlth Sci Ctr, Kochi, Japan
[7] Kitasato Univ, Sagamihara, Kanagawa, Japan
[8] Natl Kyusyu Canc Ctr, Fukuoka, Japan
[9] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[10] Saku Cent Hosp, Nagano, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.90
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
90
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II Study of ABI-007 Given as an Every Three Weeks Schedule for Japanese Patients With Unresectable or Recurrent Gastric Cancer Refractory to 5-fluorouracil (5-FU) Containing Regimen
    Nishina, T.
    Sasaki, Y.
    Yasui, H.
    Takiuchi, H.
    Tsuji, A.
    Muro, K.
    Koizumi, W.
    Toh, Y.
    Hara, T.
    Miyata, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S465 - S465
  • [2] A Phase II Trial of Nab-Paclitaxel (ABI-007) and Carboplatin in Patients With Unresectable Stage IV Melanoma A North Central Cancer Treatment Group Study, N057E
    Kottschade, Lisa A.
    Suman, Vera J.
    Amatruda, Thomas, III
    McWilliams, Robert R.
    Mattar, Bassam I.
    Nikcevich, Daniel A.
    Behrens, Robert
    Fitch, Tom R.
    Jaslowski, Anthony J.
    Markovic, Svetomir N.
    CANCER, 2011, 117 (08) : 1704 - 1710
  • [3] A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen
    Farshid Dayyani
    Kit Tam
    Edward J. Kim
    Samuel Ejadi
    Jennifer Valerin
    Thomas H. Taylor
    May T. Cho
    Medical Oncology, 39
  • [4] A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen
    Dayyani, Farshid
    Tam, Kit
    Kim, Edward J.
    Ejadi, Samuel
    Valerin, Jennifer
    Taylor, Thomas H.
    Cho, May T.
    MEDICAL ONCOLOGY, 2022, 39 (05)
  • [5] A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer
    Akihiro Nakajo
    Shuichi Hokita
    Sumiya Ishigami
    Futoshi Miyazono
    Tadaaki Etoh
    Masahiro Hamanoue
    Shigeho Maenohara
    Toshimitsu Iwashita
    Hideaki Komatsu
    Kiyoharu Satoh
    Kuniaki Aridome
    Satoshi Morita
    Shoji Natsugoe
    Hiroya Takiuchi
    Shyuji Nakano
    Yoshihiko Maehara
    Junichi Sakamoto
    Takashi Aikou
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 1103 - 1109
  • [6] A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer
    Nakajo, Akihiro
    Hokita, Shuichi
    Ishigami, Sumiya
    Miyazono, Futoshi
    Etoh, Tadaaki
    Hamanoue, Masahiro
    Maenohara, Shigeho
    Iwashita, Toshimitsu
    Komatsu, Hideaki
    Satoh, Kiyoharu
    Aridome, Kuniaki
    Morita, Satoshi
    Natsugoe, Shoji
    Takiuchi, Hiroya
    Nakano, Shyuji
    Maehara, Yoshihiko
    Sakamoto, Junichi
    Aikou, Takashi
    Taxol, Kyushu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (06) : 1103 - 1109
  • [7] A phase Ib multicenter study of trifluridine/tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma (aGEC) after at least one line of treatment with a fluoropyrimidine and platinum containing regimen.
    Dayyani, Farshid
    Tam, Kit
    Kim, Edward
    Keshtmand, Parvin
    Ejadi, Samuel
    Lee, Fa Chyi
    Cho, May Thet
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [8] A phase II, multicenter, single-arm study of parsaclisib, a PI3Kδ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.
    Zheng, Zhong
    Zhang, Huilai
    Zhou, Keshu
    Zhou, Hui
    Zhang, Li
    Li, Caixia
    Zhou, Min
    Qian, Wenbin
    Li, Zhiming
    Zhang, Qingyuan
    Cheng, Ying
    Liu, Peng
    Li, Zhenyu
    Su, Liping
    Li, Fei
    Sun, Xiuhua
    Wang, Jingwen
    Gao, Yuhuan
    Zhao, Xielan
    Zhao, Weili
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)
    Wasaburo Koizumi
    Norisuke Nakayama
    Satoshi Tanabe
    Tohru Sasaki
    Katsuhiko Higuchi
    Ken Nishimura
    Seiichi Takagi
    Mizutomo Azuma
    Takako Ae
    Kenji Ishido
    Kento Nakatani
    Akira Naruke
    Chikatoshi Katada
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 407 - 413
  • [10] A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)
    Koizumi, Wasaburo
    Nakayama, Norisuke
    Tanabe, Satoshi
    Sasaki, Tohru
    Higuchi, Katsuhiko
    Nishimura, Ken
    Takagi, Seiichi
    Azuma, Mizutomo
    Ae, Takako
    Ishido, Kenji
    Nakatani, Kento
    Naruke, Akira
    Katada, Chikatoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 407 - 413
12345